ImmunoGen, Inc. (IMGN) Financial Statements (2023 and earlier)

Company Profile

Business Address 830 WINTER ST
WALTHAM, MA 02451
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments310374438479246240283
Cash and cash equivalents310374438479246240283
Receivables1357545
Other undisclosed current assets20171414203131
Total current assets:330394457500271274320
Noncurrent Assets
Operating lease, right-of-use asset11111212131314
Property, plant and equipment4445555
Other noncurrent assets131399997
Total noncurrent assets:28282526262726
TOTAL ASSETS:359422482526297301346
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities85594847504449
Accounts payable20171618111213
Accrued liabilities56372923352933
Employee-related liabilities9535543
Deferred revenue15162344545452
Debt     12
Other undisclosed current liabilities413131082132
Total current liabilities:1048784101112120134
Noncurrent Liabilities
Long-term debt and lease obligation12131415161718
Operating lease, liability12131415161718
Liabilities, other than long-term debt39444749555861
Deferred revenue39444748525559
Other liabilities0011222
Other undisclosed noncurrent liabilities26282935373839
Total noncurrent liabilities:77859199108113117
Total liabilities:181172175200220233252
Stockholders' equity
Stockholders' equity attributable to parent178250306326776894
Common stock2222222
Additional paid in capital1,8111,8051,8001,7951,5091,4631,458
Accumulated deficit(1,635)(1,557)(1,495)(1,471)(1,434)(1,397)(1,366)
Total stockholders' equity:178250306326776894
TOTAL LIABILITIES AND EQUITY:359422482526297301346

Income Statement (P&L) ($ in millions)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Revenues1514382891716
Gross profit:1514382891716
Operating expenses(93)(75)(61)(63)(43)(44)(45)
Operating loss:(77)(61)(23)(35)(34)(27)(29)
Nonoperating income (expense)10(0)(0)(0)0(0)
Investment income, nonoperating2100000
Other nonoperating income (expense)(1)(0)(0)(0)(0)0(0)
Interest and debt expense     (0)(0)
Loss from continuing operations before equity method investments, income taxes:(77)(61)(23)(35)(35)(27)(29)
Other undisclosed loss from continuing operations before income taxes   (13)   
Loss before gain (loss) on sale of properties:(77)(61)(23)(48)(35)(27)(29)
Other undisclosed net income (loss)  (1)11  (5)
Net loss:(77)(61)(24)(37)(35)(27)(34)
Other undisclosed net loss attributable to parent(1)(1)  (3)(4) 
Net loss available to common stockholders, diluted:(78)(62)(24)(37)(37)(31)(34)

Comprehensive Income ($ in millions)

9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Net loss:(77)(61)(24)(37)(35)(27)(34)
Comprehensive loss:(77)(61)(24)(37)(35)(27)(34)
Other undisclosed comprehensive loss, net of tax, attributable to parent(1)(1)  (3)(4) 
Comprehensive loss, net of tax, attributable to parent:(78)(62)(24)(37)(37)(31)(34)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: